Diagnovus, LLC, a molecular diagnostic company focused on underserved, aggressive, and lesser-known diseases, has announced an addition to its ENGAUGE cancer assay portfolio with the launch of the ENGAUGE-cancer DLBCL Gene Panel. This genomic profile is designed to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma (DLBCL).
The assay was introduced at the American Society of Hematology Annual Meeting. The ENGAUGE-cancer DLBCL Gene Panel is a multiplexed, next-generation sequencing (NGS)-based assay for detecting genomic alterations across numerous “hotspots” in a patient’s DLBCL cancer genome. The panel, which interrogates 17 somatically altered genes, can be performed in a highly reproducible and accurate manner using routinely available formalin-fixed, paraffin-embedded (FFPE) diagnostic biopsy tissue.
The current standard of care for the treatment of most cases of DLBCL is the R-CHOP regimen, consisting of multi-agent chemotherapy plus a therapeutic antibody directed against CD20, a marker of B-lymphocytes. Despite this treatment, however, DLBCL is still incurable in about 40% of cases.
“The ENGAUGE-cancer DLBCL Gene Panel may help physicians design alternative treatments by identifying mutations in each patient’s tumor, which can help guide potential targeted therapies or clinical trials that may not be otherwise identified,” says Jeff Sharman, MD, a hematologist oncologist at the Willamette Valley Cancer Institute in Eugene, OR, and medical director of hematology research for The US Oncology Network. “Several of these genes have a functional role and are important drivers in the pathogenesis of DLBCL.” Learn more about the ENGAUGE-cancer DLBCL Gene Panel.
